Britta Randlev

3.3k total citations · 1 hit paper
14 papers, 2.6k citations indexed

About

Britta Randlev is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Britta Randlev has authored 14 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Britta Randlev's work include Virus-based gene therapy research (9 papers), CAR-T cell therapy research (7 papers) and Cancer Research and Treatments (3 papers). Britta Randlev is often cited by papers focused on Virus-based gene therapy research (9 papers), CAR-T cell therapy research (7 papers) and Cancer Research and Treatments (3 papers). Britta Randlev collaborates with scholars based in United States, United Kingdom and New Zealand. Britta Randlev's co-authors include David H. Kirn, John Nemunaitis, Fadlo R. Khuri, Carla Heise, Ian Ganly, James C. Arseneau, Patricia A. Bruso, J. Ironside, Stanley B. Kaye and Martin Gore and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Journal of Virology.

In The Last Decade

Britta Randlev

14 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

2000 858 citations Fadlo R. Khuri, John Nemunaitis et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Britta Randlev United States	10	2.1k	1.6k	1.5k	572	268	14	2.6k
Dechao Yu United States	27	1.5k 0.7×	1.4k 0.9×	1.2k 0.8×	428 0.7×	244 0.9×	57	2.7k
Frederick J. Kohlhapp United States	14	1.1k 0.5×	919 0.6×	1.3k 0.8×	260 0.5×	238 0.9×	27	2.3k
Caroline J. Breitbach Canada	28	2.5k 1.2×	1.2k 0.8×	2.1k 1.4×	538 0.9×	427 1.6×	51	3.5k
Phillip H. Gallimore United Kingdom	26	1.0k 0.5×	1.1k 0.7×	579 0.4×	173 0.3×	133 0.5×	61	1.7k
Matt Coffey United States	35	2.9k 1.4×	1.3k 0.8×	2.0k 1.3×	854 1.5×	1.1k 4.2×	98	3.6k
Anna Kanerva Finland	39	3.8k 1.8×	2.5k 1.6×	3.1k 2.0×	995 1.7×	500 1.9×	125	4.7k
Mena Mansour United States	11	565 0.3×	354 0.2×	684 0.4×	110 0.2×	103 0.4×	23	1.2k
Elizabeth J. Ilett United Kingdom	24	1.2k 0.6×	541 0.3×	1.2k 0.8×	307 0.5×	397 1.5×	38	1.9k
Victoria Roulstone United Kingdom	21	980 0.5×	425 0.3×	698 0.5×	290 0.5×	385 1.4×	34	1.3k
Shaoheng Ni United States	23	1.7k 0.8×	1.3k 0.8×	905 0.6×	284 0.5×	470 1.8×	27	2.1k

Countries citing papers authored by Britta Randlev

Since Specialization

Citations

This map shows the geographic impact of Britta Randlev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Britta Randlev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Britta Randlev more than expected).

Fields of papers citing papers by Britta Randlev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Britta Randlev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Britta Randlev. The network helps show where Britta Randlev may publish in the future.

Co-authorship network of co-authors of Britta Randlev

This figure shows the co-authorship network connecting the top 25 collaborators of Britta Randlev. A scholar is included among the top collaborators of Britta Randlev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Britta Randlev. Britta Randlev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Palma, Enzo, Britta Randlev, Sheila Ulufatu, et al.. (2011). Abstract A138: Evaluation of neonatal Fc receptor (FcRn) expression and function in tumor cell lines and their potential effect on IgG disposition in solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). A138–A138. 2 indexed citations

Randlev, Britta, et al.. (2010). Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products. Biologicals. 38(2). 249–259. 4 indexed citations

Galanis, Evanthia, Scott H. Okuno, Antonio G. Nascimento, et al.. (2005). Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy. 12(5). 437–445. 130 indexed citations

Lochrie, Michael A., Shangzhen Zhou, Jennifer Wellman, et al.. (2005). Novel Caprine Adeno-Associated Virus (AAV) Capsid (AAV-Go.1) Is Closely Related to the Primate AAV-5 and Has Unique Tropism and Neutralization Properties. Journal of Virology. 79(24). 15238–15245. 66 indexed citations

Nemunaitis, John, Charles Cunningham, A W Tong, et al.. (2003). Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Therapy. 10(5). 341–352. 70 indexed citations

Reid, Tony, E. Galanis, James L. Abbruzzese, et al.. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.. PubMed. 62(21). 6070–9. 251 indexed citations

Nemunaitis, John, Casey Cunningham, Gerald M. Edelman, et al.. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Therapy. 8(10). 746–759. 228 indexed citations

Mulvihill, Sean J., Robert S. Warren, Alan P. Venook, et al.. (2001). Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy. 8(4). 308–315. 221 indexed citations

Nemunaitis, John, Fadlo R. Khuri, Ian Ganly, et al.. (2001). Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer. Journal of Clinical Oncology. 19(2). 289–298. 369 indexed citations

10.

Khuri, Fadlo R., John Nemunaitis, Ian Ganly, et al.. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine. 6(8). 879–885. 858 indexed citations breakdown →

11.

Nemunaitis, John, Ian Ganly, Fadlo R. Khuri, et al.. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.. PubMed. 60(22). 6359–66. 331 indexed citations

12.

Busse, William W., Britta Randlev, & Julie B. Sedgwick. (1989). The effect of azelastine on neutrophil and eosinophil generation of superoxide. Journal of Allergy and Clinical Immunology. 83(2). 400–405. 60 indexed citations

13.

Busse, William W., et al.. (1989). Effect of Nedocromil Sodium on the β-Adrenergic Response of Human Polymorphonuclear Leucocytes1. Drugs. 37(Supplement 1). 26–31. 3 indexed citations

14.

Randlev, Britta, et al.. (1988). 175 The effect of azelastime (AZ) un neutrophil and eosinophil generation of superoxide (O2−). Journal of Allergy and Clinical Immunology. 81(1). 212–212. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact